BJMO - volume 8, issue 2, may 2014
R. A. Popescu , R. Schäfer , R. Califano , R. Eckert , R. Coleman , J.-Y. Douillard , A. Cervantes , P. G. Casali , C. Sessa , E. van Cutsem MD, PhD, E. de Vries , N. Pavlidis MD, PhD, K. Fumasoli , B. Wörmann , H. Samonigg , S. Cascinu , J. J. Cruz Hernández , A. J. Howard , F. Ciardiello , R. A. Stahel , M. Piccart MD, PhD
The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries. Medical oncology is a core member of the MDT and offers cancer patients a comprehensive and systemic approach to treatment and care, while ensuring evidence-based, safe and cost-effective use of cancer drugs and preserving the quality of life of cancer patients through the entire ‘cancer journey’. Medical oncologists are also engaged in clinical and translational research to promote innovation and new therapies and they contribute to cancer diagnosis, prevention and research, making a difference for patients in a dynamic, stimulating professional environment. Medical oncologists play an important role in shaping the future of healthcare through innovation and are also actively involved at the political level to ensure a maximum contribution of the profession to Society and to tackle future challenges. This position paper summarises the multifarious and vital contributions of medical oncology and medical oncologists to today’s and tomorrow’s professional cancer care.
Reprinted from Annals of Oncology 2014;25(1):9–15 with permission of Oxford University Press.
(BELG J MED ONCOL 2014;8(2):30–7)
Read moreBJMO - volume 6, issue 1, february 2012
A. Stoyianni MD, PhD, G. Pentheroudakis MD, PhD, N. Pavlidis MD, PhD
Epithelial-mesenchymal transitions (EMT) occur as key steps during embryonic morphogenesis and are now implicated in the progression of primary tumours towards metastases, but also towards the accumulation of stem-cell properties. Recent advances have fostered a more detailed understanding of molecular mechanisms and networks governing EMT and leading to more dedifferentiated and malignant states. Owing to the clinical importance of the EMT-induced processes, inhibition of EMT is an attractive therapeutic approach that could have significant effect on disease outcome.
(BELG J MED ONCOL 2012;6:3–12)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
